OrthoPediatrics Corp. (NASDAQ:KIDS) Insider Gregory A. Odle Sells 5,359 Shares

OrthoPediatrics Corp. (NASDAQ:KIDS) insider Gregory A. Odle sold 5,359 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total value of $133,224.74. Following the completion of the transaction, the insider now owns 148,788 shares of the company’s stock, valued at approximately $3,698,869.68. The trade was a 3.48 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

OrthoPediatrics Stock Up 1.8 %

KIDS stock opened at $25.42 on Wednesday. The firm’s fifty day moving average is $24.79 and its 200 day moving average is $25.53. The firm has a market cap of $617.38 million, a PE ratio of -20.67 and a beta of 1.22. OrthoPediatrics Corp. has a one year low of $21.02 and a one year high of $35.99. The company has a debt-to-equity ratio of 0.19, a quick ratio of 3.68 and a current ratio of 7.17.

OrthoPediatrics (NASDAQ:KIDS) last announced its quarterly earnings results on Tuesday, March 4th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.04. The firm had revenue of $52.67 million during the quarter, compared to analyst estimates of $51.16 million. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. During the same quarter in the previous year, the business earned ($0.23) EPS. On average, research analysts forecast that OrthoPediatrics Corp. will post -0.93 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on KIDS. Stifel Nicolaus decreased their price objective on shares of OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, March 5th. Truist Financial cut their price target on OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating on the stock in a research report on Wednesday, December 18th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $42.00 target price on shares of OrthoPediatrics in a report on Wednesday, March 5th.

Institutional Investors Weigh In On OrthoPediatrics

A number of institutional investors have recently added to or reduced their stakes in KIDS. Millennium Management LLC acquired a new stake in shares of OrthoPediatrics in the fourth quarter valued at about $9,798,000. Point72 Asset Management L.P. acquired a new stake in OrthoPediatrics during the 4th quarter worth $7,450,000. Wasatch Advisors LP grew its holdings in shares of OrthoPediatrics by 47.2% during the fourth quarter. Wasatch Advisors LP now owns 696,318 shares of the company’s stock worth $16,141,000 after buying an additional 223,217 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of OrthoPediatrics by 20.2% in the fourth quarter. Wellington Management Group LLP now owns 1,061,299 shares of the company’s stock worth $24,601,000 after buying an additional 178,078 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in OrthoPediatrics by 29.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 671,968 shares of the company’s stock worth $15,576,000 after purchasing an additional 152,681 shares in the last quarter. Institutional investors and hedge funds own 69.05% of the company’s stock.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.